Monoclonal Antibodies Elimination in Breast Cancer Patient
This Study evaluates covariables being able to potentially influence the elimination of the monoclonal antibodies (trastuzumab, bevacizumab and denosumab).
Breast Cancer
OTHER: additional blood sample
clearance of the bevacizumab, 9 months
clearance of the trastuzumab, 9 months
Monoclonal antibodies are very widely used in cancer treatment . Certain patients benefit from these antibodies for several years and it is conceivable to wonder about the evolution of the pharmacokinetics of these antibodies.